Mark Walker

Mark Walker

Auto-generated profile, based on publicly available information

Mark Walker

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Current Cardiology Reports
Verified
Journal Article
Open access
PDF file
ABAudrey E. Brown
Audrey E. Brown
MWMark Walker
Mark Walker
Insulin resistance and the metabolic syndrome are complex metabolic traits and key risk factors for the development of cardiovascular disease. They result from the interplay of environmental and genetic factors but the full extent of the genetic background to these conditions remains incomplete. Large-scale genome-wide association studies have helped advance the identification of common genetic variation associated with insulin resistance and the metabolic syndrome, and more recently, exome sequencing has allowed the identification of rare variants associated with the pathogenesis of these conditions. Many variants associated with insulin resistance are directly involved in glucose metabolism; however, functional studies are required to assess the contribution of other variants to the development of insulin resistance. Many genetic variants involved in the pathogenesis of the metabolic syndrome are associated with lipid metabolism.

13 February 2004 in Diabetologia
Verified
Journal Article
Closed access
PDF file
GMG. W. Mills
G. W. Mills
JLJ. C. Levy
J. C. Levy
MSM. Sampson
M. Sampson
MWM. Walker
M. Walker
PAP. J. Avery
P. J. Avery
MMM. I. McCarthy
M. I. McCarthy

5 June 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
LCL. M. Cree
L. M. Cree
SPSheila Patel
Sheila Patel
APA. Pyle
A. Pyle
SLS. Lynn
S. Lynn
DTD. M. Turnbull
D. M. Turnbull
MWM. Walker
M. Walker

1 January 2015 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
ABAudrey E. Brown
Audrey E. Brown
JPJane Palsgaard
Jane Palsgaard
RBRehannah Borup
Rehannah Borup
PAPeter Avery
Peter Avery
DGDavid A. Gunn
David A. Gunn
MWMark Walker
Mark Walker
Skeletal muscle is the key site of peripheral insulin resistance in type 2 diabetes. Insulin-stimulated glucose uptake is decreased in differentiated diabetic cultured myotubes, which is in keeping with a retained genetic/epigenetic defect of insulin action. We investigated differences in gene expression during differentiation between diabetic and control muscle cell cultures. Microarray analysis was performed using skeletal muscle cell cultures established from type 2 diabetic patients with a family history of type 2 diabetes and clinical evidence of marked insulin resistance and nondiabetic control subjects with no family history of diabetes. Genes and pathways upregulated with differentiation in the diabetic cultures, compared with controls, were identified using Gene Spring and Gene Set Enrichment Analysis. Gene sets upregulated in diabetic myotubes were associated predominantly with inflammation. p38 MAPK was identified as a key regulator of the expression of these proinflammatory gene sets, and p38 MAPK activation was found to be increased in the diabetic vs. control myotubes. Although inhibition of p38 MAPK activity decreased cytokine gene expression from the cultured diabetic myotubes significantly, it did not improve insulin-stimulated glucose uptake. Increased cytokine expression driven by increased p38 MAPK activation is a key feature of cultured myotubes derived from insulin-resistant type 2 diabetic patients. p38 MAPK inhibition decreased cytokine expression but did not affect the retained defect of impaired insulin action in the diabetic muscle cells.

22 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DNDonna L. Nile
Donna L. Nile
ABAudrey E. Brown
Audrey E. Brown
MKMeutia A. Kumaheri
Meutia A. Kumaheri
HBHelen R. Blair
Helen R. Blair
AHAlison Heggie
Alison Heggie
MWMark Walker
Mark Walker
Type 2 diabetes is characterised by an age-related decline in insulin secretion. We previously identified a 50% age-related decline in mitochondrial DNA (mtDNA) copy number in isolated human islets. The purpose of this study was to mimic this degree of mtDNA depletion in MIN6 cells to determine whether there is a direct impact on insulin secretion. Transcriptional silencing of mitochondrial transcription factor A, TFAM, decreased mtDNA levels by 40% in MIN6 cells. This level of mtDNA depletion significantly decreased mtDNA gene transcription and translation, resulting in reduced mitochondrial respiratory capacity and ATP production. Glucose-stimulated insulin secretion was impaired following partial mtDNA depletion, but was normalised following treatment with glibenclamide. This confirms that the deficit in the insulin secretory pathway precedes K+ channel closure, indicating that the impact of mtDNA depletion is at the level of mitochondrial respiration. In conclusion, partial mtDNA depletion to a degree comparable to that seen in aged human islets impaired mitochondrial function and directly decreased insulin secretion. Using our model of partial mtDNA depletion following targeted gene silencing of TFAM, we have managed to mimic the degree of mtDNA depletion observed in aged human islets, and have shown how this correlates with impaired insulin secretion. We therefore predict that the age-related mtDNA depletion in human islets is not simply a biomarker of the aging process, but will contribute to the age-related risk of type 2 diabetes.

31 January 2003 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SLS. Lynn
S. Lynn
GBG. M. Borthwick
G. M. Borthwick
RCR. M. Charnley
R. M. Charnley
MWM. Walker
M. Walker
DTD. M. Turnbull
D. M. Turnbull